Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 4/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741562 | 1.00 | BRD4 (0.35) | BRD4SPHK1CNR1GPR119KDM4E | |
| SCHEMBL6741524 | 0.81 | SPHK1 (0.38) | BRD4SPHK1CNR1GPR119CPB2 | |
| SCHEMBL6736498 | 0.81 | SPHK1 (0.38) | BRD4SPHK1CNR1GPR119CPB2 | |
| SCHEMBL9705697 | 0.72 | GRIN2B (0.34) | CNR1GPR119MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL223310 | 0.70 | KLK7 (0.39) | BRD4SPHK1GPR119MEN1KMT2A | |
| SCHEMBL223309 | 0.70 | KLK7 (0.39) | BRD4SPHK1GPR119MEN1KMT2A | |
| SCHEMBL2741064 | 0.70 | KLK7 (0.39) | BRD4SPHK1GPR119MEN1KMT2A | |
| SCHEMBL31153714 | 0.69 | SPHK1 (0.32) | BRD4SPHK1 | |
| SCHEMBL31536674 | 0.69 | SPHK1 (0.41) | BRD4SPHK1 | |
| SCHEMBL30302061 | 0.69 | KLK7 (0.38) | BRD4SPHK1GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142975-A1 | Beta disubstituted metalloprotease inhibitors | THE PROCTER &GAMBLE COMPANY | 2004-07-22 | — | — | US | disclosed |
| US-6696456-B1 | CARBOCYCLIC ACIDS AND SALTS SUCH AS (2S,3R)-3-ETHYLSULFANYL-2-(4'-FLUORO-BIPHENYL-4-SULFONYLAMINO)-3- PHENYLPROPIONIC ACID, USED AS METALLOENZYME ANTAGONISTS FOR THE PROPHYLAXIS OF DEGENERATIVE JOINT DISEASE AND AS WOUND HEALING AGENTS | THE PROCTER & GAMBLE COMPANY | 2004-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142975-A1 | Beta disubstituted metalloprotease inhibitors | ADAM17, ADAM9, SI | BRD4 2561/4885SPHK1 1998/4885CNR1 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.